Abstract
Considerable research efforts have focused on the discovery of safe and efficacious acyl-CoA cholesterol acyltransferase (ACAT) inhibitors as cholesterol-lowering and/or antiatherosclerotic agents. Although clinical success remains elusive, recent developments in the molecular biology of ACAT and success in identifying potent and bioavailable inhibitors that are not adrenotoxic has led to renewed hope that ACAT inhibition may ultimately yield agents that will have value in treating human atherosclerotic disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
